NPPA computed the Retail Price of Empagliflozin 25 mg + Linagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release) for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Macleods Pharmaceuticals Ltd. (Marketer)

Aug 16, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific Compliance

The National Pharmaceutical Pricing Authority (NPPA) on August 11, 2026, issued the Computation of Retail Price of Empagliflozin 25 mg + Linagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)' for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Macleods Pharmaceuticals Ltd. (Marketer).

The following has been stated namely: -

• The Retail Price has been computed based on the data from December 2025

• The Retail Price has been computed for Each Film Coated Tablet Containing Empagliflozin 25 mg + Linagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)' for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Macleods Pharmaceuticals Ltd. (Marketer).

• The Total MAT is 5,21,60,164

[Notification No. 19(5275)/2026/DP/NPPA/Div.II]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT